Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Thiogenesis Therapeutics Corp. has announced progress in its clinical programs for mitochondrial diseases, highlighting its upcoming Phase 2 trial for MELAS in Europe and a planned Phase 2a trial for Leigh Syndrome in partnership with a leading US children’s hospital. These developments underscore the company’s commitment to addressing rare mitochondrial disorders using its novel thiol compounds.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.